Immunic Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Immunic wird ein Gewinn- und Umsatzwachstum von 67% bzw. 90.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 67.1% pro Jahr wachsen soll.

Wichtige Informationen

67.0%

Wachstumsrate der Gewinne

67.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	90.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 25

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:IMUX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-106	-108	-104	6
12/31/2025	N/A	-96	-100	-93	7
12/31/2024	N/A	-97	-92	-92	7
9/30/2024	N/A	-97	-76	-76	N/A
6/30/2024	N/A	-95	-73	-72	N/A
3/31/2024	N/A	-98	-76	-75	N/A
12/31/2023	N/A	-94	-71	-71	N/A
9/30/2023	N/A	-129	-72	-72	N/A
6/30/2023	N/A	-127	-68	-68	N/A
3/31/2023	N/A	-125	-64	-64	N/A
12/31/2022	N/A	-120	-65	-65	N/A
9/30/2022	N/A	-85	-74	-74	N/A
6/30/2022	N/A	-83	-78	-78	N/A
3/31/2022	N/A	-79	-91	-91	N/A
12/31/2021	N/A	-93	-83	-83	N/A
9/30/2021	N/A	-83	-74	-74	N/A
6/30/2021	N/A	-77	-68	-68	N/A
3/31/2021	N/A	-70	-48	-48	N/A
12/31/2020	N/A	-44	-46	-46	N/A
9/30/2020	N/A	-41	-39	-38	N/A
6/30/2020	N/A	-36	-33	-32	N/A
3/31/2020	N/A	-39	-34	-34	N/A
12/31/2019	N/A	-35	-29	-29	N/A
9/30/2019	N/A	-32	-26	-26	N/A
6/30/2019	N/A	-26	-22	-22	N/A
3/31/2019	N/A	-14	-13	-13	N/A
12/31/2018	N/A	-12	-10	-10	N/A
9/30/2018	N/A	-10	-10	-10	N/A
12/31/2017	N/A	-10	N/A	-10	N/A
12/31/2016	0	-1	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMUX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: IMUX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: IMUX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: IMUX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: IMUX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMUX in 3 Jahren voraussichtlich hoch sein wird

Immunic Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 13% to US$11.90

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased by 32% to US$9.00

Forecast to breakeven in 2026

Recent updates

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors